BRPI0606143A2 - terapia de combinação - Google Patents
terapia de combinaçãoInfo
- Publication number
- BRPI0606143A2 BRPI0606143A2 BRPI0606143-5A BRPI0606143A BRPI0606143A2 BR PI0606143 A2 BRPI0606143 A2 BR PI0606143A2 BR PI0606143 A BRPI0606143 A BR PI0606143A BR PI0606143 A2 BRPI0606143 A2 BR PI0606143A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapy
- combination
- drug
- scd
- inhibitors
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
Abstract
TERAPIA DE COMBINAçãO. Esta invenção está direcionada ao uso de inibidores de SCD-1 da Fórmula (I): onde x, y, V, W, G, J, L, M, R^ 2^, R^ 3^, R^ 5^, R^ 5a^, R^ 6^, R^ 6a^, R^ 7^, R^ 7a^, R^ 8^ e R^ 8a^ são de- finidos aqui, em combinação com outras terapias de fármaco para tratar o ganho de peso adverso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65158405P | 2005-02-09 | 2005-02-09 | |
| PCT/US2006/004383 WO2006086445A2 (en) | 2005-02-09 | 2006-02-08 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0606143A2 true BRPI0606143A2 (pt) | 2009-06-02 |
Family
ID=36603292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606143-5A BRPI0606143A2 (pt) | 2005-02-09 | 2006-02-08 | terapia de combinação |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7919484B2 (pt) |
| EP (1) | EP1846035B1 (pt) |
| JP (1) | JP2008530097A (pt) |
| CN (1) | CN101163504A (pt) |
| AR (1) | AR053331A1 (pt) |
| AT (1) | ATE525088T1 (pt) |
| AU (1) | AU2006212761B2 (pt) |
| BR (1) | BRPI0606143A2 (pt) |
| CA (1) | CA2597067A1 (pt) |
| GT (1) | GT200600046A (pt) |
| MX (1) | MX2007009592A (pt) |
| TW (1) | TW200638945A (pt) |
| WO (1) | WO2006086445A2 (pt) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005011654A2 (en) * | 2003-07-29 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
| WO2007009236A1 (en) * | 2005-07-20 | 2007-01-25 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2007071023A1 (en) | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AR059355A1 (es) | 2006-02-07 | 2008-03-26 | Wyeth Corp | Inhibidores de 11-beta hsd1 |
| CA2666398C (en) | 2006-10-17 | 2015-08-18 | Ed Kisak | Diclofenac gel |
| TW200826936A (en) | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AR064965A1 (es) | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
| EP2142529B1 (en) * | 2007-04-27 | 2013-12-25 | Purdue Pharma LP | Trpv1 antagonists and uses thereof |
| EP2152270B1 (en) | 2007-06-08 | 2015-03-04 | Janssen Pharmaceutica, N.V. | Piperidine/piperazine derivatives |
| ES2483898T3 (es) * | 2007-06-08 | 2014-08-08 | Janssen Pharmaceutica, N.V. | Derivados de piperidina/piperazina |
| JP5443342B2 (ja) | 2007-06-08 | 2014-03-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピペリジン/ピペラジン誘導体 |
| JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
| US7842696B2 (en) | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| ES2499018T3 (es) | 2007-09-20 | 2014-09-26 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de GPR119 |
| PE20100083A1 (es) | 2008-06-05 | 2010-02-17 | Janssen Pharmaceutica Nv | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
| WO2010028761A1 (de) * | 2008-09-09 | 2010-03-18 | Sanofi-Aventis | 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren |
| US20110183958A1 (en) * | 2008-10-17 | 2011-07-28 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CN102316892B (zh) * | 2009-02-12 | 2014-06-04 | 西马生物医学计划公司 | 心肌营养素-1用于治疗代谢病的用途 |
| WO2010094120A1 (en) | 2009-02-17 | 2010-08-26 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US8546450B1 (en) | 2009-03-31 | 2013-10-01 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
| US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
| GB0907425D0 (en) * | 2009-04-29 | 2009-06-10 | Glaxo Group Ltd | Compounds |
| US8383643B2 (en) | 2009-07-28 | 2013-02-26 | Merck Canada Inc. | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| US20110101885A1 (en) * | 2009-11-02 | 2011-05-05 | Eric Yang | Led backlight circuit for lcd panels |
| KR101701943B1 (ko) | 2009-11-13 | 2017-02-02 | 도레이 카부시키가이샤 | 당뇨병의 치료 또는 예방약 |
| US9428478B2 (en) | 2011-06-13 | 2016-08-30 | Emory University | Piperazine derivatives, compositions, and uses related thereto |
| RS55701B1 (sr) | 2011-06-22 | 2017-07-31 | Purdue Pharma Lp | Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe |
| MX2014014174A (es) | 2012-05-22 | 2015-07-06 | Hoffmann La Roche | Inhibidores selectivos de celulas no diferenciadas. |
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| US12486250B2 (en) | 2019-12-06 | 2025-12-02 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2024148148A1 (en) * | 2023-01-04 | 2024-07-11 | The Trustees Of Columbia University In The City Of New York | Pyridazine based small molecule inhibitor of cognitive impairment |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9614238D0 (en) * | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
| EP1100511A2 (en) * | 1998-06-08 | 2001-05-23 | Sambasiva R. Chavali | Inhibition of delta-9-desaturase activity by saponins |
| US20030064950A1 (en) * | 2001-02-23 | 2003-04-03 | Ntambi James M. | Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity |
| EP1388352A1 (en) | 2002-08-08 | 2004-02-11 | Laboratoires Fournier S.A. | Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment |
| AU2003294446A1 (en) | 2002-11-21 | 2004-06-18 | Bayer Pharmaceuticals Corporation | Regulation of stearoyl-coa desaturase to treat obesity |
| US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
| US20060258683A1 (en) * | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
| EP2316827B1 (en) * | 2003-07-30 | 2016-01-27 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
-
2006
- 2006-02-07 GT GT200600046A patent/GT200600046A/es unknown
- 2006-02-08 MX MX2007009592A patent/MX2007009592A/es not_active Application Discontinuation
- 2006-02-08 BR BRPI0606143-5A patent/BRPI0606143A2/pt not_active IP Right Cessation
- 2006-02-08 AU AU2006212761A patent/AU2006212761B2/en not_active Ceased
- 2006-02-08 WO PCT/US2006/004383 patent/WO2006086445A2/en not_active Ceased
- 2006-02-08 AT AT06734555T patent/ATE525088T1/de not_active IP Right Cessation
- 2006-02-08 EP EP06734555A patent/EP1846035B1/en not_active Expired - Lifetime
- 2006-02-08 JP JP2007555181A patent/JP2008530097A/ja active Pending
- 2006-02-08 US US11/815,739 patent/US7919484B2/en not_active Expired - Fee Related
- 2006-02-08 CN CNA2006800097246A patent/CN101163504A/zh active Pending
- 2006-02-08 CA CA002597067A patent/CA2597067A1/en not_active Abandoned
- 2006-02-09 TW TW095104441A patent/TW200638945A/zh unknown
- 2006-02-09 AR ARP060100465A patent/AR053331A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE525088T1 (de) | 2011-10-15 |
| JP2008530097A (ja) | 2008-08-07 |
| AU2006212761A1 (en) | 2006-08-17 |
| AU2006212761B2 (en) | 2009-07-02 |
| WO2006086445A2 (en) | 2006-08-17 |
| EP1846035A2 (en) | 2007-10-24 |
| CA2597067A1 (en) | 2006-08-17 |
| EP1846035B1 (en) | 2011-09-21 |
| MX2007009592A (es) | 2007-10-16 |
| AR053331A1 (es) | 2007-05-02 |
| WO2006086445A3 (en) | 2006-09-14 |
| US20090131447A1 (en) | 2009-05-21 |
| TW200638945A (en) | 2006-11-16 |
| WO2006086445A8 (en) | 2006-12-07 |
| US7919484B2 (en) | 2011-04-05 |
| GT200600046A (es) | 2006-09-25 |
| CN101163504A (zh) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200600046A (es) | Terapia de combinacion | |
| CY1116763T1 (el) | Ιμιδαζοτριαζινες με ιμιδαζοπυριμιδινες ως αναστολεις κινασης | |
| NO20070049L (no) | Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| ECSP088503A (es) | COMPUESTOS de LACTAMa y MÉTODOS DE USO DE LOS MISMOS | |
| CY1112206T1 (el) | Παραγωγα πυριδαζινονης για την θεραπεια ογκων | |
| EA200970738A1 (ru) | Ингибиторы активности akt | |
| NO20082414L (no) | Inhibitorer av AKT-aktivitet | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| BR0314235A (pt) | Compostos de fenil-aza-benzimidazol para modulação de ige e inibição da proliferação celular | |
| PL1896470T3 (pl) | Pochodne pirolopirydynowe jako inhibitory kinazy białkowej | |
| MX2009006535A (es) | Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina. | |
| ATE368657T1 (de) | Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren | |
| CU20070160A7 (es) | Pirrolopirazoles, inhibidores potentes de quinasa | |
| MXJL03000027A (es) | Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular. | |
| CY1113314T1 (el) | (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης | |
| NO20075849L (no) | Fremgangsmater og preparater til behandling eller forebygging av kreft | |
| ATE512151T1 (de) | Pyrrolotriazin-kinaseinhibitoren | |
| ATE520668T1 (de) | Sigmarezeptor-inhibitoren | |
| NO20093542L (no) | Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer | |
| CL2007002384A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis. | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
| EA200800014A1 (ru) | Аминохинолиновые и аминохиназолиновые модуляторы киназы | |
| TW200630367A (en) | Substituted adenines and the uses thereof | |
| CR8696A (es) | Beta-carbolinas utiles para tratar enfermedades inflamatorias | |
| UA99434C2 (ru) | Применение производных алкилфосфолипидов со сниженной цитотоксичностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |